Consequently, considering the correlation between MASLD onset and metabolic function, it is essential to further examine the impact of PNPLA3 inhibition on other metabolic-related diseases. This evidence concerns the gene PNPLA3 and metabolic dysfunction-associated steatotic liver disease.